| |
| |
Rimoslim - Generic Acomplia / Zimulti 20mg
Product: Rimoslim / Generic Acomplia / Zimulti
Drug Name: Rimonabant
Packaging Type: Strips of 10 x 20mg tablets
Manufacturer: Torrent
| Rimoslim (Rimonabant 20mg) Prices |
| 90 tablets of Rimoslim (Rimonabant 20mg) |
US$81.00 |
 Buy Rimoslim |
| 120 tablets of Rimoslim (Rimonabant 20mg) |
US$108.00 |
Buy Rimoslim |
| 150 tablets of Rimoslim (Rimonabant 20mg) |
US$135.00 |
Buy Rimoslim |
Rimoslim Information
Generic Acomplia / Zimulti (Rimoslim) is an anorectic anti-obesity drug (causes a reduction in appetite)
Generic Acomplia / Zimulti (Rimoslim) works by blocking receptors called cannabinoid-1 receptors: CB1.
CB1 receptors can be found in the brain, fat tissue, liver, digestive system and muscles.
Overactivation of the CB1 receptors is associated with increased appetite, cravings for food and fat build-up.
Generic Rimonabant (Rimoslim) blocks CB1 receptors and helps decrease appetite and reduces cravings for food.
Generic Rimonabant (Rimoslim) may also reduce blood levels of "bad fats" and increase blood levels of "good fats" called HDL-cholesterol and.
Generic Acomplia / Zimulti (Rimoslim) can also help people to quit smoking.
Rimoslim Intake Guidelines
Usually you should take one tablet daily in the morning before breakfast.
Do not take more than your doctor has prescribed.
Rimoslim Side Effects
The most common side effects of Generic Acomplia (Rimoslim) include:
-
Irritability
- Stomach upset
- Anxiety
- Dizziness
- Depression
- Nausea
- Nervousness
- Fatigue
Rimoslim Warnings
Women who are or who may become pregnant must not take Generic Acomplia / Zimulti (Rimoslim).
Generic Acomplia / Zimulti (Rimoslim) should not be taken when breast-feeding.
You should tell your doctor if you are breast-feeding or if you are planning to breast-feed your baby.
It is important to continue to follow a diet and exercise program after treatment with this medicine to help you maintain any weight loss.
Tell your doctor if you have or have ever had kidney or liver disease.
| |
|
|
|
|
